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early-phase trial of dose-
per-fractioneescalated con-
current chemoradiation for
NSCLC. Tumor doses of 63
to 73 Gy (mean, 67.7 Gy)
were isotoxically prescribed
to the ICRU reference point
and delivered in 30 fractions
over 40 days. Toxicity was
acceptable. At 35 months’
median follow-up, median
OS was 36.9 months, 1-year
OS and PFS were 87.8% and
72.0%, and 2-year OS and
PFS were 68.0% and 48.5%.were assigned to 1 of 2 groups according to esophageal dose. In group 1, tumor doses
were determined by an experimental constraint on maximum esophageal dose, which
was escalated following a 6 þ 6 design from 65 Gy through 68 Gy to 71 Gy, allowing
an esophageal maximum tolerated dose to be determined from early and late toxic-
ities. Tumor doses for group 2 patients were determined by other tissue constraints,
often lung. Overall survival, progression-free survival, tumor response, and toxicity
were evaluated for both groups combined.
Results: Eight centers recruited 84 patients: 13, 12, and 10, respectively, in the 65-Gy,
68-Gy, and 71-Gy cohorts of group 1; and 49 in group 2. The mean prescribed tumor dose
was 67.7 Gy. Five grade 3 esophagitis and 3 grade 3 pneumonitis events were observed
across both groups. After 1 fatal esophageal perforation in the 71-Gy cohort, 68 Gy was
declared the esophageal maximum tolerated dose.With a median follow-up of 35months,
median overall survival was 36.9 months, and overall survival and progression-free sur-
vival were 87.8% and 72.0%, respectively, at 1 year and 68.0% and 48.5% at 2 years.
Conclusions: IDEAL-CRTachieved significant treatment intensification with acceptable
toxicity and promising survival. The isotoxic design allowed the esophageal maximum
tolerated dose to be identified from relatively few patients.  2016 The Authors. Pub-
lished by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Intensification of local treatment has been associated
with increased local control and overall survival (OS) for
non-small cell lung cancer (NSCLC) patients. Improved
2-year OS was reported for CHART (Continuous
Hyperfractionated Accelerated Radiotherapy) trial pa-
tients treated using 54 Gy delivered in just 12 days
compared with the standard 60 Gy in 40 days (29% vs
20%) (1), and a recent meta-analysis has reported a
hazard ratio (HR) of 0.86 for intensification of radiation-
only or sequential chemoradiotherapy (CRT) treatments
compared with control arms (2). A meta-analysis of trials
of concurrent versus sequential CRT found an advantage
for concurrent delivery of radiation and chemotherapy,
with an HR of 0.77 for local progression-free survival
(PFS) and 5.7% and 4.5% absolute benefit in OS at 3 and
5 years, respectively (3).
Radiation Therapy Oncology Group protocol 0617
recently examined the effect of increasing radiation therapy
(RT) tumor doses from 60 to 74 Gy given in 5 2-Gy frac-
tions per week (4). Unexpectedly, survival was significantly
lower in the 74-Gy arm, perhaps partly because the 11-day
increase in total treatment time required for additional
fractions reduced the effectiveness of tumor dose escala-
tion. Dose-per-fraction escalation circumvents this by
fixing the number of fractions and treatment duration,
hypofractionating and effectively accelerating RT (5-7). It
may therefore provide a more effective means of local
treatment intensification (8-10).
Radiation therapy toxicity is determined by doses
delivered to normal tissues. Early-phase trials testing the
toxicity of intensified CRT or RT combined with novel
agents should control these normal tissue doses, whileallowing prescribed tumor doses to vary within an accept-
able range. Isotoxic dose escalation accomplishes this by
prescribing the highest deliverable tumor doses without
exceeding predetermined normal tissue limits.
We report toxicity and early survival data for IDEAL-
CRT, a trial of tumor doseeescalated concurrent CRT for
NSCLC. Dose-per-fraction escalation was used to achieve
intensification without schedule protraction; tumor doses
were prescribed isotoxically; and selected patients were
prospectively assigned to cohorts receiving incrementally
increasing esophageal RT doses.Patients and Methods
This nonrandomized phase 1/2 trial enrolled stage II and III
NSCLC patients, who received tumor RT doses between
63 Gy and 73 Gy in 30 once-daily fractions over 40 days,
concurrent with 2 cycles of cisplatin and vinorelbine.
Patients
Inclusion criteria were histologically/cytologically
confirmed stage IIA-IIIB NSCLC, World Health Organi-
zation performance status (PS) 0 to 1, suitability for CRT
agreed by multidisciplinary team, no prior anticancer
therapy, forced expiratory volume 40% predicted or
1 L, carbon monoxide diffusing capacity 40% pre-
dicted, hematology and biochemistry baselines suitable for
chemotherapy, and glomerular filtration rate 60 mL/min.
Patients with chronic liver disease and/or bilirubin
>35 mmol/L, connective tissue disorders (eg, scleroderma,
systemic lupus), or history of prior malignancy likely to
interfere with protocol treatment were excluded.
Table 1 Summary of the radiation therapy planning and dose prescription process
Process steps
Tumor coverage aim
PTV 90% isodose to cover 98% of PTV
Tumor dose prescribed to the ICRU reference point initially selected to achieve
Lung EQD2mean 18.2 Gy
Prescribed tumor dose reduced by 10%, and further if needed to meet the following limits
Heart D100% <45 Gy, D67% <53 Gy, D33% <60 Gy
Spinal cord D0.1cc  47 Gy
Brachial plexus D30% 60 Gy, D0.1cc 65 Gy
Esophagus Dose to 1 cm3Z65 Gy Dose to 1 cm3Z68 Gy Dose to 1 cm3Z71 Gy Dose to 1 cm3 63 Gy*
Limit for Group 1: cohort 1 Group 1: cohort 2 Group 1: cohort 3 Group 2
Abbreviations: EQD2mean Z equivalent dose in 2-Gy fractions averaged across lung, excluding gross tumor volume (GTV); ICRU Z International
Commission on Radiation Units and Measurements; PTV Z planning target volume.
Prescribed tumor dose finally limited to 63-73 Gy, patients being ineligible for the trial if this causes lung V20Gy (the volume of lung excluding GTV
receiving more than 20 Gy) or EQD2mean to exceed 35% or 19.3 Gy, respectively.
* This dose level increased to 65 Gy, and then 68 Gy as safety data became available from group 1.
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Patients received the highest prescribed tumor doses between
63 and 73Gydeliverablewhilemeeting the normal tissue dose
constraints shown in Table 1. For lungs, spinal cord, brachial
plexus, and heart these constraints were held at levels deter-
mined from an earlier review (11). However, insufficient data
linking dose to toxicity existed for an esophageal constraint to
be defined up front, and so an incrementally increasing
esophageal limit was used during the trial. To facilitate this
process, patients were split after RT treatment planning but
before tumor dose prescription into 2 nonrandomized groups
based on dosimetric findings. In group 1, prescribed tumor
doses were limited by an escalating esophageal constraint,
whereas in group 2 prescribed tumor doses were limited by
lung and other normal tissue constraints. Allocation of pa-
tients to these groups was therefore determined purely on the
basis of dosimetry and not clinician choice.
Group 1 was designed as a phase 1 study to establish an
esophageal maximum tolerated dose (MTD), patients’
prescribed tumor doses being limited by an escalating
experimental constraint on dose delivered to the most
highly irradiated 1 cm3 of esophagus. This esophageal dose
constraint was progressively raised from 65 Gy to 68 Gy
and then 71 Gy, following a 6 þ 6 design (Fig. E1; avail-
able online at www.redjournal.org), treating 6 or 12 patients
at each level. It was initially planned to include a 73-Gy
esophageal dose cohort, but the 73-Gy upper limit on pre-
scribed tumor dose meant that in practice it was not feasible
to deliver 73 Gy to 1 cm3 of esophagus. Dose-limiting
toxicities were grade 3 esophagitis (Common Terminol-
ogy Criteria for Adverse Events, version 4.0) occurring
during or within 4 weeks of completing RT and late
esophageal toxicity, which was monitored closely.
Group 2 comprised all trial patients whose prescribed
tumor doses were limited by other dose constraints, often
lung or cord, and was designed to provide further toxicity
data, particularly for radiation pneumonitis (RTPN). For
some group 2 patients, however, prescribed tumor dose waslimited by a lower esophageal constraint, already known to
be safe, initially set at 63 Gy to 1 cm3 (Table 1). As the trial
recruited, this group 2 esophageal limit was progressively
raised to levels for which early toxicity had been found to be
acceptable in cohorts of 12 patients in group 1.
Feasibility and survival data were analyzed jointly across
both groups, comprising the phase 2 element of the study.
Interventions
Concurrent chemotherapy was 2 cycles of intravenous
cisplatin (75 mg/m2) on days 1 and 29 of RT, and intra-
venous vinorelbine (15 mg/m2) on days 1, 8, 29, and 36. No
induction or consolidation chemotherapy was allowed.
Radiation therapy planning was the same for groups 1
and 2. Three-dimensional (3D) or 4-dimensional (4D) CT
images were collected during quiet breathing, and on 3D-
CT images the gross tumor volume (GTV) was contoured
and then expanded by 5 mm to create a clinical target
volume and by a further 5-mm minimum radial and 10-mm
minimum cranio-caudal to form a planning target volume.
On 4D-CT, a composite volume was formed by merging
GTVs outlined on the different scan phases, then expanded
by 5 mm to form a clinical target volume and by 5 mm
minimum further in all directions to form a planning target
volume. Most patients were treated using 3D conformal
plans comprising 3 to 5 photon fields of energy 5 to 8 MV.
Some were treated using volumetric modulated arc therapy
(VMAT), according to available center resources. Dose
distributions were calculated using “type-b” super-
positioneconvolution algorithms (12), and all tumor doses
were prescribed to the International Commission on Radi-
ation Units and Measurements (ICRU) reference point.
The tumor dose prescription process is summarized in
Table 1. For each patient an initial prescribed tumor dose
was selected to achieve a target value of 18.2 Gy for lung
EQD2mean, the average equivalent dose in 2-Gy fractions
delivered to all CT voxels of both lungs excluding the GTV
(13, 14). This level is associated with a 20% rate of
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presumed grade 3 to 5 rate of <10% (13, 15). The pre-
scribed tumor dose was then reduced by 10% to allow for
toxicity caused by concurrent chemotherapy, and further if
necessary to meet the tabulated dose constraints for
esophagus, brachial plexus, heart, and spinal cord (11). If
this caused the prescribed tumor dose to fall below the trial
minimum of 63 Gy, the lung EQD2mean limit was relaxed to
19.3 Gy, and the patient would still receive a prescribed
tumor dose of 63 Gy provided this relaxed lung limit and all
the other normal tissue constraints listed in Table 1 could be
met. Prescribed tumor doses were capped at 73 Gy to limit
damage to central blood vessels and airways.
Quality assurance was overseen by the Radiotherapy
Trials Quality Assurance Group of the National Cancer
Research Institute. Before starting the trial, clinicians and
physicists from each center attended an outlining and dose
prescription workshop. Clinicians outlined 2 benchmark
cases (16), which were checked against contours drawn by
the principal investigator, and planned 2 pre-outlined
benchmark cases, which were reviewed to ensure that
trial dosimetric aims were met. An additional arc-planned
case was checked for centers introducing VMAT. Equip-
ment details were collected via an online questionnaire.
Contouring and dosimetry of each center’s first recruited
case was independently reviewed before treatment. Further
reviews were requested, where deemed necessary, to ensure
protocol compliance. Subsequently all treatment plan data
were collected centrally and analyzed retrospectively to
verify conformance to the trial protocol.Table 2 Demographics and baseline characteristics of all patients
Characteristic Group 1 (nZ35)
Age (y)
70 10 (29)
<70 25 (71)
Mean (SD) 65.6 (8.0)
Median (range) 66 (46-84)
Sex
Female 9 (26)
Male 26 (74)
WHO PS
0 12 (34)
1 23 (66)
Histology
Adenocarcinoma 12 (34)
Squamous 17 (49)
Other NSCLC 6 (17)
Stage
IIA 0
IIB 0
IIIA 24 (69)
IIIB 11 (31)
GTV size (cm3)
Mean (SD) 127.7 (118.9)
Median (range) 110 (14-602)
Abbreviations: GTV Z gross tumor volume; NSCLC Z non-small cell lun
Values are number (percentage) unless otherwise noted.Staging CT of the thorax and abdomen and positron
emission tomography scanning were performed for all pa-
tients, either one within 42 days of commencing RT. Clinical
assessments of PS, hematology, weight, and dyspnea score
were made weekly during RT. Posttreatment PS, weight,
dyspnea score, pulmonary function, adverse events, and
toxicity data were collected at clinical reviews held weekly
during the first month, monthly to 6 months, every 3 months
to 24 months, every 6 months to 36 months, and annually
thereafter. Computed tomography thorax and abdomen and
lung function tests were carried out 3, 6, 12, and 24 months
after completion of RT, chest X ray at 1, 3, 6, 12, 18, and
24 months, and electrocardiogram at 6 and 12 months.Outcomes and statistics
Trial endpoints were toxicity, particularly esophagitis and
RTPN, OS, PFS, and tumor response (RECIST version 1.1).
Attribution of toxicity to treatment was overseen by
an independent data monitoring committee. Rates of OS and
PFS were estimated using Kaplan-Meier methods. All pa-
tients who received at least 1 fraction of RTwere included in
this analysis. The database cutoff date was July 31, 2015.
The group 1 sample size depended on toxicity seen: up
to 36 patients were possible, 12 each in the 3 feasible co-
horts. In group 2, assuming a grade 2 to 5 RTPN rate of
20% was of further interest, 45 patients were required to
exclude an unacceptable rate of 40% with a 1-sided 5%
significance level and 90% power (17).Group 2 (nZ49) Total (nZ84)
13 (27) 23 (27)
36 (73) 61 (73)
65.4 (8.0) 65.5 (8.0)
66 (43-78) 66 (43-84)
13 (27) 22 (26)
36 (73) 62 (74)
20 (41) 32 (38)
29 (59) 52 (62)
14 (29) 26 (31)
30 (61) 47 (56)
5 (10) 11 (13)
0 0
6 (12) 6 (7)
33 (67) 57 (68)
10 (20) 21 (25)
118.0 (83.3) 122.1 (99.4)
92 (15-329) 109 (14-602)
g cancer; WHO PS Z World Health Organization performance status.
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The funder, Cancer Research UK, was not involved in
the conduct, analysis, or interpretation of the trial, or the
writing of this report. The trial sponsor, responsible for
trial conduct and analysis, was University College
London. The corresponding author had full access
to all the data in the study and final responsibility
to submit for publication. The trial was run in accor-
dance with the Declaration of Helsinki and with the
approval of all relevant ethical bodies and regulatory
authorities.84 patients re
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Between September 2010 and March 2013, 84 patients
from 8 UK centers were enrolled, 35 in group 1 and 49 in
group 2, with the baseline characteristics shown in Table 2.
Of these, 34 patients (40.5%) were planned using 4D-CT
and 50 (59.5%) with intravenous contrast. Three patients
were treated using VMAT. An extra patient was recruited to
the 65-Gy cohort of group 1 because replanning during
treatment was required for 1 of the patients initially
recruited, adding uncertainty to the delivered maximum
esophageal dose. Twelve patients were recruited to the 68-gistered
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Fig. 2. Radiation therapy tumor doses delivered to the International Commission on Radiation Units and Measurements
reference point.
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funding ended (Fig. 1).
Two patients in group 2 did not begin treatment
following clinical deterioration. Of the 82 patients starting
CRT, 81 (98.8%) completed both cycles of chemotherapy,
and 81 (98.8%) received all 30 RT fractions (Fig. 1); 1
patient withdrew due to toxicity (group 2). Median relative
dose intensity was 99.6% for cisplatin and 99.0% for
vinorelbine, and RT was generally delivered as scheduled,
with a median duration of 5.6 weeks (range, 5.1-6.6 weeks;
Table E1; available online at www.redjournal.org). Pre-
scribed tumor doses are shown in Figure 2 and have an
overall mean of 67.7 Gy, with means of 68.9 Gy and
66.8 Gy for groups 1 and 2, respectively.
Toxicity
Grade 2 to 5 RTPN was seen in 30.5% of patients who
received trial treatment (1-sided upper 95% confidence
limit 39.9%; 2-sided 95% confidence interval [CI] 20.8%-
41.6%). Three of these RTPN events were grade 3 (3.7%;
95% CI 0.8%-10.3%).
The grade 2 to 5 esophagitis rate overall was 82.9% (2-
sided 95% CI 73.0%-90.3%), with 5 grade 3 toxicities
(6.1%; 2-sided 95% CI 2.0%-13.7%). A fatal esophageal
perforation occurred in 1 patient in the 71-Gy cohort of
group 1, 7 months after RT (Table 3), and was considered
directly related to treatment. The esophageal MTD was
therefore set at 68 Gy to 1 cm3 of esophagus.
A further 3 patients had fatal events (Table 3), all he-
moptysis. One occurred 14 months after RT with tumor
recurrence and was considered possibly treatment related(group 1, prescribed tumor dose 72.6 Gy); another at
4.5 months after RT with residual tumor was considered
unrelated (group 2, prescribed tumor dose 68.5 Gy); and the
third at 4 weeks after RT was also considered unrelated
(group 2, prescribed tumor dose 67.6 Gy).
Incidences of esophagitis and RTPN are listed by grade
and trial group in Table 3, alongside a summary of other
toxicities. Rates of other complications are listed in more
detail in Table E2 (available online at www.redjournal.org),
and the latency of grade 3 to 5 toxicities is summarized in
Table E3 (available online at www.redjournal.org). Table
E4 (available online at www.redjournal.org) summarizes
the trial dosimetrically, listing prescribed tumor doses for
all 3 cohorts of group 1 and for group 2, alongside details of
delivered doses to the constrained normal tissues.
Efficacy
At the 3 months post-RT visit, 52 patients (63.4%) had a
partial response, 21 (25.6%) had stable disease, 4 (4.9%)
had progressive disease, 4 (4.9%) had non-evaluable dis-
ease, and 1 (1.2%) patient had died.
After a median follow-up of 34.9 months (range, 2.2-
51.2 months) there were 40 deaths, the remaining 42 pa-
tients being censored at the last date known to be alive.
One- and 2-year OS was 87.8% (95% CI 80.7%-94.9%)
and 68.0% (95% CI: 57.8%-78.1%), respectively, and me-
dian OS was 36.9 months (95% CI 31.7-42.1 months)
(Fig. 3a). Overall survival is plotted by tumor stage in
Figure 3b. Figure 3c shows OS for the 82 patients split into
2 subgroups having prescribed tumor doses greater or less
than the 68-Gy median; the risk of death was lower for the
Table 3 Selected toxicities by grade among the 82 patients who began radiation therapy (safety population), according to trial group
Toxicity Grade Group 1 (nZ35) Group 2 (nZ47) Total (NZ82)
Esophagitis 0 2 (6) 7 (15) 9 (11)
1 1 (3) 4 (9) 5 (6)
2 30 (86) 33 (70) 63 (77)
3 2 (6) 3 (6) 5 (6)
4 0 0 0
5 0 0 0
RTPN* 0 11 (31) 24 (51) 35 (43)
1 12 (34) 10 (21) 22 (27)
2 10 (29) 12 (26) 22 (27)
3 2 (6) 1 (2) 3 (4)
4 0 0 0
5 0 0 0
All toxicities grades 3 25 (71) 36 (77) 61 (74)
3 20 (57) 26 (55) 46 (56)
4 3 (9) 8 (17) 11 (13)
5y 2 (6) 2 (4) 4 (5)
Grade 3%z hematologic
White blood cell decreased 2 (6) 9 (19) 11 (13)
Lymphocyte decreased 1 (3) 8 (17) 9 (11)
Neutrophil decreased 4 (11) 8 (17) 12 (15)
Grade 3 other
Lung infection 9 (26) 9 (19) 18 (22)
FEV decreased 5 (14) 7 (15) 12 (15)
Abbreviation: FEV Z forced expiratory volume.
Values are number (percentage).
* RTPNZ radiation therapy pneumonitis. Two patients received higher lung doses than allowed in the protocol. Both received prescribed tumor doses
of 63 Gy, one with a lung V20 of 46.5% and one with 40.7%. Neither experienced RTPN.
y Four patients had grade 5 events: in group 1, 1 patient experienced esophageal perforation and 1, hemoptysis. Two group 2 patients experienced
hemoptysis.
z There were no relevant hemoglobin-related events.
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PZ.06). There were 49 PFS events overall. One- and two-
year PFS was 72.0% (95% CI 62.2%-81.7%) and 48.5%
(95% CI: 37.6%-59.3%), respectively, and median PFS was
21.1 months (95% CI 11.5-30.6 months) (Fig. 3d).Discussion
IDEAL-CRT tested a novel, individualized, tumor-dose-
per-fraction escalated concurrent CRT schedule for
NSCLC. The trial demonstrated acceptable toxicity, feasi-
bility, and promising clinical outcomes, as well as defining
an esophageal MTD for the schedule.
The 6% rate of grade 3 to 5 esophagitis in IDEAL-CRT
is lower than the 18% and 25% average rates found in 2
meta-analyses of concurrent CRT (3, 18) and the 7%,
19%, and 26% rates of the 2 dose arms of Radiation
Therapy Oncology Group (RTOG) 0617 (4) and the
MAASTRO study of isotoxically individualized concur-
rent CRT (10). Intensive clinical input resulting from
mandated weekly patient assessments may have reduced
the number of grade 3 to 5 cases in IDEAL-CRT, and the
study’s dosimetric focus may also have limited esopha-
geal irradiation.There was 1 late grade 3 to 5 esophageal toxicity, a fatal
perforation in the 71-Gy cohort of trial group 1, and 68 Gy
was defined as the esophageal MTD. Of 171 patients treated
using concurrent CRT at Netherlands Cancer Institute,
Amsterdam, 3 suffered esophageal fistula and 8, grade 3
stenosis (19). In the high-dose arm of RTOG 0617, 3 of 206
patients died of gastrointestinal toxicity (20), and an addi-
tional 9 of 442 patients overall experienced late grade 3 to 5
gastrointestinal toxicity (4). The most significant predictor
of late esophageal toxicity in The Netherlands Cancer
Institute series was esophageal volume receiving an EQD2
76.7 Gy. Using the linear-quadratic model with an a/b ratio
of 3 Gy to account for fractionation differences (14), this
equates to the 71-Gy esophageal dose level of the IDEAL-
CRT cohort in which the esophageal perforation occurred.
The ability of the isotoxic escalation scheme to limit the
incidence of RTPN was confirmed by the grade 2 to 5 RTPN
and grade 3 to 5 RTPN rates of 30.5% (95% CI 20.8%-
41.6%) and 3.7% (95% CI 0.8%-10.3%), respectively, in the
patients who received trial treatment, similar to the 7% and
4% grade 3 to 5 rates of the control and escalated arms of
RTOG 0617, and the 7% rate in the Cochrane review of
concurrent CRT (18). A detailed analysis of possible asso-
ciations between dosimetry; observed pulmonary, cardiac,
and esophageal toxicities and survival is underway.
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Fig. 3. (continued).
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the Cochrane review, treatment-related deaths were recor-
ded in 3% of patients receiving concurrent CRT (18). In
RTOG 0617, 8 treatment-related deaths occurred in the 74-
Gy group, versus 7 in the 60-Gy group, and 10 patients
receiving cetuximab had treatment-related deaths versus 5
not receiving cetuximab (4). Overall, despite substantial
treatment intensification, toxicity in IDEAL-CRT does not
seem higher than in other relevant concurrent CRT studies.
IDEAL-CRT patients were recruited and treated at
multiple sites, supported by a rigorous quality assurance
program (21). Their demographics and tumor characteris-
tics were roughly comparable to those of patients in pre-
vious studies (Table 2) (3, 4). The average prescribed tumor
dose of 67.7 Gy in 30 fractions corresponds to a 15% in-
crease in EQD2 above the 60-Gy dose given in 30 fractions
in the control arm of RTOG 0617, assuming a 10 Gy a/b
ratio for NSCLC (14, 15). Although it remains to be proven
in randomized trials whether this degree of intensification
improves survival, the 36.9-month median OS seen in
IDEAL-CRT is promising and compares well with median
OS times of 28.7 and 20.3 months, respectively, in the
control and escalated arms of RTOG 0617, and with
24.3 months in the concurrent CRT arm of the United
Kingdom SOCCAR trial (4, 22).
The relatively high survival seen in IDEAL-CRT may
originate from strict adherence to the CRT protocol, as well
as from treatment intensification. It might also reflect the
stage-mix of patients (7% stage IIB, more stage IIIA than
IIIB), although we found no evidence of a difference in OS
between IIIA and IIIB patients (HR 1.23; 95% CI 0.59-
2.57; PZ.58) (Fig. 3b). The borderline-significant survival
advantage seen for patients treated with prescribed doses
greater than the median could be interpreted as showing an
increase in tumor control either with rising dose or with
falling tumor size, because isotoxic schemes tend to pre-
scribe higher doses to smaller tumors.
A key feature of IDEAL-CRT was its focus on doses to
organs at risk, particularly in determining the safety of
progressively increasing esophageal doses in a sequence
of patient cohorts. Although it is not possible to plan
exactly the same RT dose distribution in each patient, we
have nevertheless demonstrated the feasibility of struc-
tured patient recruitment to cohorts defined by key dosi-
metric predictors of toxicity. This aspect of trial design
proved to be effective and efficient in prospectively
identifying an MTD for esophagus using relatively few
patients, and is highly relevant to early-phase studies
investigating intensified RT across many tumor types and
sites and to studies exploring the addition to RT of sys-
temic therapies, radiosensitizers, or radioprotectors.Conclusions
Toxicity results and survival data from IDEAL-CRT
are promising. Dose limits have been determinedefficiently using the study’s approach to dose escalation,
namely by incrementally increasing key dose metrics in
specific normal tissues. We have recently completed
recruitment to a 5-week form of the IDEAL-CRT schedule,
designed to further limit tumor repopulation during treat-
ment, and are presently planning a randomized trial of the
6-week schedule described here versus standard dose CRT.References
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